CONTEXT: Cycling androgens has been reported by athletes to improve physical performance by enhancing muscle mass and strength, a paradigm that has not been studied, and may have clinical value in older men being treated withtestosterone. OBJECTIVE: We investigated the efficacy of a monthly cycled testosterone regimen that uses half the testosterone dose as the current standard of care continuous therapy on body composition and muscle strength in older men. DESIGN, SETTING, AND PATIENTS: Twenty-four community-dwelling older men 70± 2 yr of age with total testosterone levels below 500 ng/dl were randomized at the Institute for Translational Sciences-Clinical Research Center into a 5-month double-blind placebo-controlled trial. INTERVENTION: Subjects were dosed weekly for 5 months, receiving continuous testosterone (TE, n = 8; 100 mg testosterone enanthate, im injection), monthly cycled testosterone (MO, n = 8; alternating months of testosterone and placebo), or placebo (PL, n = 8). MAIN OUTCOME MEASURES: Main outcomes included body composition by dual-energy x-ray absorptiometry and upper and lower body muscle strength. Secondary outcomes included body weight, serum hormones, and mixed-muscle protein fractional synthesis rate (FSR). RESULTS:Total lean body mass was increased and percent fat was reduced after 5 months in TE and MO (P < 0.05). Upper body muscle strength increased in TE, and lower body muscle strength increased in TE and MO (P < 0.05). FSR increased in TE and MO (P < 0.05) but not in PL. CONCLUSIONS:Cycled testosterone improved body composition and increased muscle strength compared with placebo and increased FSR similarly to continuous testosterone.
RCT Entities:
CONTEXT: Cycling androgens has been reported by athletes to improve physical performance by enhancing muscle mass and strength, a paradigm that has not been studied, and may have clinical value in older men being treated with testosterone. OBJECTIVE: We investigated the efficacy of a monthly cycled testosterone regimen that uses half the testosterone dose as the current standard of care continuous therapy on body composition and muscle strength in older men. DESIGN, SETTING, AND PATIENTS: Twenty-four community-dwelling older men 70 ± 2 yr of age with total testosterone levels below 500 ng/dl were randomized at the Institute for Translational Sciences-Clinical Research Center into a 5-month double-blind placebo-controlled trial. INTERVENTION: Subjects were dosed weekly for 5 months, receiving continuous testosterone (TE, n = 8; 100 mg testosterone enanthate, im injection), monthly cycled testosterone (MO, n = 8; alternating months of testosterone and placebo), or placebo (PL, n = 8). MAIN OUTCOME MEASURES: Main outcomes included body composition by dual-energy x-ray absorptiometry and upper and lower body muscle strength. Secondary outcomes included body weight, serum hormones, and mixed-muscle protein fractional synthesis rate (FSR). RESULTS: Total lean body mass was increased and percent fat was reduced after 5 months in TE and MO (P < 0.05). Upper body muscle strength increased in TE, and lower body muscle strength increased in TE and MO (P < 0.05). FSR increased in TE and MO (P < 0.05) but not in PL. CONCLUSIONS: Cycled testosterone improved body composition and increased muscle strength compared with placebo and increased FSR similarly to continuous testosterone.
Authors: S Bhasin; T W Storer; N Berman; C Callegari; B Clevenger; J Phillips; T J Bunnell; R Tricker; A Shirazi; R Casaburi Journal: N Engl J Med Date: 1996-07-04 Impact factor: 91.245
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Fabian Chen; Raymond Lam; David Shaywitz; Ronald C Hendrickson; Gregory J Opiteck; Dana Wishengrad; Andy Liaw; Qinghua Song; Adrian J Stewart; Corinne E Cummings; Chan Beals; Kevin E Yarasheski; Alise Reicin; Marcella Ruddy; Xuguang Hu; Nathan A Yates; Joseph Menetski; Gary A Herman Journal: J Cachexia Sarcopenia Muscle Date: 2011-02-26 Impact factor: 12.910
Authors: Meghan E Downs; Jessica M Scott; Lori L Ploutz-Snyder; Robert Ploutz-Snyder; Elizabeth Goetchius; Roxanne E Buxton; Christopher P Danesi; Kathleen M Randolph; Randall J Urban; Melinda Sheffield-Moore; E Lichar Dillon Journal: Life Sci Space Res (Amst) Date: 2020-05-20
Authors: Randall J Urban; E L Dillon; S Choudhary; Y Zhao; A M Horstman; R G Tilton; M Sheffield-Moore Journal: Trans Am Clin Climatol Assoc Date: 2014
Authors: Melinda Sheffield-Moore; John E Wiktorowicz; Kizhake V Soman; Christopher P Danesi; Michael P Kinsky; Edgar L Dillon; Kathleen M Randolph; Shannon L Casperson; Dennis C Gore; Astrid M Horstman; James P Lynch; Barbara M Doucet; Joni A Mettler; Jeffrey W Ryder; Lori L Ploutz-Snyder; Jean W Hsu; Farook Jahoor; Kristofer Jennings; Gregory R White; Susan D McCammon; William J Durham Journal: Clin Transl Sci Date: 2013-10-29 Impact factor: 4.689
Authors: Jessica M Scott; David Martin; Robert Ploutz-Snyder; Meghan Downs; E Lichar Dillon; Melinda Sheffield-Moore; Randall J Urban; Lori L Ploutz-Snyder Journal: Med Sci Sports Exerc Date: 2018-09 Impact factor: 5.411
Authors: E Lichar Dillon; Melinda Sheffield-Moore; William J Durham; Lori L Ploutz-Snyder; Jeffrey W Ryder; Christopher P Danesi; Kathleen M Randolph; Charles R Gilkison; Randall J Urban Journal: Med Sci Sports Exerc Date: 2018-09 Impact factor: 5.411
Authors: Mahalakshmi Shankaran; Chelsea L King; Thomas E Angel; William E Holmes; Kelvin W Li; Marc Colangelo; John C Price; Scott M Turner; Christopher Bell; Karyn L Hamilton; Benjamin F Miller; Marc K Hellerstein Journal: J Clin Invest Date: 2015-12-14 Impact factor: 14.808